Trust Signals
Key Takeaways
- BPC-157 is not FDA-approved. The FDA placed it on the Category 2 bulk drug substances list in 2023, creating meaningful compliance risk for compounding pharmacies.
- All human efficacy data is either anecdotal or from very small, non-replicated pilot studies. Every positive healing claim rests almost entirely on rodent models from Sikiric's group.
- Research chemical suppliers are not GMP-regulated. Independent third-party testing has found purity variance across suppliers, with some products below the 98 percent threshold expected for pharmaceutical-grade peptide.
- BPC-157 is on the WADA prohibited list. Athletes subject to anti-doping rules cannot use it regardless of how it was sourced.
- The correct molecular weight for authentic BPC-157 is 1419.55 Da. A mass spec confirmation on a COA is the single most reliable identity check available to a consumer.
Direct Answer: How Do You Get BPC-157?
How to get BPC-157 depends on your jurisdiction and risk tolerance. In the US, the two practical routes are a compounding pharmacy with a prescriber's order, or a research chemical supplier with no regulatory oversight. Neither route is FDA-approved, and the compounding pathway became more restricted after the FDA's 2023 Category 2 nomination. There is no fully clean, mainstream medical channel.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What is the legal status of BPC-157 in the US?
- Can you get BPC-157 from a compounding pharmacy?
- What are research chemical suppliers and are they safe?
- What does the evidence actually show? (Evidence Ledger)
- How is BPC-157 supposed to work, with specific numbers?
- What most pages get wrong about obtaining BPC-157
- How to read a COA and judge product quality
- Honest head-to-head: BPC-157 vs. real alternatives
- How should BPC-157 be stored, and why does it degrade?
- WADA status and anti-doping implications
- Frequently Asked Questions
What Is the Legal Status of BPC-157 in the US?
BPC-157 occupies a regulatory gray zone. It is not a scheduled controlled substance under the DEA's Controlled Substances Act, meaning simple possession is not a criminal offense for individuals. However, it is not an approved drug under the Federal Food, Drug, and Cosmetic Act, so it cannot be legally marketed or sold for human use.
The key 2023 development: the FDA added BPC-157 to its Category 2 nominated bulk drug substances list during its 503A and 503B compounding review process. Category 2 means the FDA has determined there is insufficient evidence of clinical utility to permit its routine use in compounding. Some 503A pharmacies (those filling individual prescriptions) may still prepare it under certain state-law interpretations, but the regulatory foundation is shaky and evolving. 503B outsourcing facilities face a harder compliance barrier.
Outside the US: Canada, Australia, and the UK have similar "unapproved drug" classifications. Australia's TGA has specifically listed it as a prohibited import without a valid permit. Always verify your country's current rules before seeking it.
Can You Get BPC-157 From a Compounding Pharmacy?
Some 503A compounding pharmacies in the US will still prepare BPC-157 when a licensed prescriber submits an order for a specific patient. The practical steps are:
- Find a functional medicine or integrative medicine physician willing to write the order. These are most commonly found through direct-pay or concierge practices, not standard insurance-based primary care.
- The physician writes an order for a specific patient's individual need (not a standing stock formula).
- The pharmacy compounds and ships directly to the patient.
Cost through this channel typically runs higher than research suppliers, often $150 to $300 or more for a month's supply, and insurance does not cover it. The quality advantage is that licensed compounding pharmacies are inspected and are incentivized to use tested raw materials. The disadvantage is that the FDA's Category 2 designation means the legal ground is narrowing, and some pharmacies have stopped compounding it entirely.
What Are Research Chemical Suppliers and Are They Safe?
Research chemical suppliers synthesize or source BPC-157 peptide, lyophilize it, and sell vials typically containing 5 mg powder. Some publish COAs. Some use third-party labs. The key risks:
- Purity variance: Independent testing organizations including Janoshik Analytical have published results showing that peptide purity across vendors varies meaningfully, with some products falling below 95 percent purity by HPLC. Impurities in peptide synthesis can include truncated sequences and residual synthesis reagents.
- Sterility is not guaranteed: Injectable-grade product requires endotoxin and sterility testing. Most research suppliers do not perform or publish sterility testing.
- No chain of custody: The raw peptide is typically synthesized in China and repackaged domestically. Quality control at the synthesis stage is outside the supplier's control unless they independently test incoming material.
- Dosing accuracy: If a vial labeled "5 mg" actually contains 4.2 mg due to purity or fill error, every dose calculation is wrong.
What Does the Evidence Actually Show?
| Claim | Best Evidence Type | Effect Direction | Confidence | Honest Caveat |
|---|---|---|---|---|
| Accelerates tendon healing | Multiple rodent RCTs (Sikiric et al., various) | Positive in animals | Moderate (for animals), Very Low (for humans) | No human RCT published |
| Promotes gut mucosal healing | Rodent models, mechanism studies | Positive in animals | Moderate (for animals), Very Low (for humans) | No peer-replicated human trial |
| Reduces gut inflammation (IBD-type models) | Rodent colitis models | Positive in animals | Low | Rodent IBD models do not consistently translate to human disease |
| Bone healing | Rodent fracture models | Positive in animals | Low | No human data |
| Safe in humans at community-reported doses | Anecdotal, no systematic adverse event reporting | No serious events formally reported | Very Low | Absence of reported harm reflects absence of trials, not proven safety |
| Effective via oral route in humans | Animal studies, mechanistic reasoning | Uncertain | Very Low | Human oral bioavailability is unmeasured |
How Is BPC-157 Supposed to Work, with Specific Numbers?
BPC-157 (Body Protective Compound 157) is a 15-amino-acid peptide derived from a protein found in gastric juice. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Molecular weight: 1419.55 Da.
The proposed mechanisms with what is actually known:
- Nitric oxide pathway modulation: Animal studies suggest BPC-157 interacts with the nitric oxide system. Research by Sikiric's group indicates effects on eNOS activity, which would explain observed vascular and healing effects in rodent models. The specific binding target and receptor are not fully characterized in peer-reviewed literature.
- Growth hormone receptor interaction: Some published work proposes that BPC-157 upregulates growth hormone receptor expression in tendon fibroblasts in rodent tissue. This is a mechanism, not a proven clinical effect pathway in humans.
- Angiogenesis: Rodent wound-healing studies have shown increased VEGF expression and capillary density in treated tissue. The magnitude of this effect varies across studies.
- FAK and paxillin signaling: Cell culture work has shown BPC-157 can activate focal adhesion kinase (FAK) and paxillin pathways involved in cell migration and proliferation. This is in vitro evidence, which is the weakest form for predicting clinical outcomes.
What these mechanisms do NOT prove: that a given oral or subcutaneous dose in a human produces sufficient tissue-level concentrations to activate these pathways. Pharmacokinetic data in humans is absent from the published literature.
What Most Pages Get Wrong About Obtaining BPC-157
This is the section commodity pages skip entirely.
The lyophilization quality problem: BPC-157 is sold as a lyophilized (freeze-dried) powder. Proper lyophilization requires a validated freeze-drying cycle that preserves peptide structure without introducing moisture. Poorly lyophilized product can have residual moisture above 1 to 2 percent by weight, which accelerates hydrolytic degradation during storage. You cannot detect this visually. A vial that appears fine and dissolves normally may contain degraded peptide if it was improperly processed or shipped without temperature control.
The reconstitution pH issue: BPC-157 is typically reconstituted in bacteriostatic water (0.9 percent benzyl alcohol, pH roughly 5.0 to 7.0). The peptide's stability is pH-dependent. Using sterile water without a stabilizing buffer accelerates oxidation. Using acidic diluents not designed for peptide reconstitution changes the degradation kinetics. Most supplier instructions give no pH guidance at all.
Shipping without cold chain: Many research suppliers ship at ambient temperature for cost reasons. Even if the lyophilized powder is more stable than reconstituted solution, extended heat exposure during shipping degrades peptide purity over time. A vial that sat in a hot delivery truck for two days is not equivalent to one that was cold-shipped.
The "research use only" label does not equal a purity guarantee: This label is a legal disclaimer. It does not mean the product was tested only in animals or that it meets research-grade chemical standards. It means the seller declines liability for human use. The product quality can range from pharmaceutical-adjacent to unreliable depending on the supplier's sourcing and testing practices.
How to Read a COA and Judge Product Quality
When evaluating any BPC-157 product, a Certificate of Analysis should contain the following to carry meaningful weight:
| COA Element | What to Look For | Why It Matters |
|---|---|---|
| HPLC purity | Greater than or equal to 98 percent | Confirms peptide purity by peak area; below 95 percent indicates significant impurities |
| Mass spectrometry (MS) | Molecular ion peak matching 1419.55 Da | Confirms you have BPC-157, not a different peptide |
| Endotoxin (LAL test) | Less than 1 EU/mg for injectable use | High endotoxin causes fever and systemic inflammation on injection |
| Sterility test | Negative for bacterial and fungal growth | Critical for injectable products; often absent on research supplier COAs |
| Lab performing the test | Independent third-party lab, not in-house | Supplier's own in-house COA has inherent conflict of interest |
| Lot number matches vial | Should be printed on vial label | A COA without a matching lot number may not describe what you received |
Honest Head-to-Head: BPC-157 vs. Real Alternatives
| Comparison | BPC-157 | Alternative | Where BPC-157 Loses |
|---|---|---|---|
| Tendon and ligament healing vs. physical therapy plus NSAIDs | Animal data positive; no human RCT | PT plus NSAIDs: human trial evidence, standard of care | No comparative human data; loses on evidence quality entirely |
| Gut healing vs. approved IBD therapies (mesalamine, biologics) | Rodent colitis models, mechanism studies | Mesalamine, vedolizumab: large phase 3 RCTs | Not even close on evidence; no human IBD trial published |
| Soft tissue repair vs. TB-500 (thymosin beta-4 fragment) | More published animal data, broader tissue models | TB-500: similar animal evidence, different mechanism (actin regulation) | Neither has human RCTs; roughly equal evidence weakness |
| Anti-inflammatory vs. low-dose naltrexone (LDN) | Mechanism plausible, no human RCT | LDN: some small human trials in Crohn's and fibromyalgia | LDN has at least small human trial data; BPC-157 does not |
How Should BPC-157 Be Stored, and Why Does Chemistry Demand It?
Lyophilized powder: store at 2 to 8 degrees Celsius, protected from light and moisture. Stable for months to a couple of years at these conditions if packaging integrity is maintained. The reason: peptide bonds in dry powder are relatively stable because hydrolysis requires water. However, oxidation of methionine residues and asparagine deamidation can still occur slowly even in dry conditions if temperature is elevated.
After reconstitution: the peptide is now in aqueous solution and hydrolysis proceeds continuously. Refrigerate at 2 to 8 degrees Celsius and plan to use within approximately 4 weeks. The chemistry: amide bond hydrolysis is catalyzed by both acid and base, proceeds faster at higher temperatures (Arrhenius relationship), and is irreversible. Freeze-thaw cycles should be avoided because ice crystal formation can mechanically disrupt peptide structure and concentration gradients during refreezing accelerate localized degradation.
Light degradation: UV exposure drives photooxidation of aromatic amino acid residues. Keeping vials in opaque or amber containers is not cosmetic; it materially slows this pathway.
WADA Status and Anti-Doping Implications
BPC-157 is listed on the World Anti-Doping Agency (WADA) Prohibited List under Section 2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. It is prohibited in-competition and out-of-competition for athletes subject to WADA-compliant anti-doping rules.
WADA-accredited laboratories have validated detection methods for BPC-157 in urine. The detection window depends on dose and individual metabolism, but the analytical methods exist. If you compete in any sport governed by a WADA signatory organization (which includes most professional and Olympic-level sports, and many collegiate programs), using BPC-157 is a potential anti-doping rule violation regardless of your intent or the source of the product.
Frequently Asked Questions
How do you get BPC-157 legally in the United States?
In the US, BPC-157 is not FDA-approved as a drug. The most defensible legal route is through a licensed compounding pharmacy operating under a valid prescriber-patient relationship. The FDA placed BPC-157 on its Category 2 nominated substances list in 2023, complicating but not fully eliminating compounding options depending on state law and the specific compounding category.
What did the FDA say about BPC-157 in 2023?
In 2023, the FDA nominated BPC-157 for review under its bulk drug substances list. It was placed on the Category 2 list, meaning it lacks adequate clinical evidence to be used in compounding. This does not make possession illegal for individuals, but it signals that compounding pharmacies face increasing compliance risk when preparing it.
Can a doctor prescribe BPC-157?
No physician can write an FDA-approved prescription for BPC-157 because no such approval exists. Some practitioners in integrative or functional medicine clinics do direct patients to compounding pharmacies or research chemical suppliers, but this operates in a regulatory gray zone and the clinical liability falls entirely on the prescriber and patient.
What are research chemical suppliers and are they safe?
Research chemical suppliers sell BPC-157 labeled "for research use only, not for human consumption." These products are not manufactured under pharmaceutical GMP standards. Purity and sterility are not guaranteed by any regulatory body. Independent lab testing by organizations like Janoshik has found significant variance in peptide purity across suppliers, with some products testing below 95 percent stated purity.
What is the difference between injectable and oral BPC-157?
Injectable BPC-157 is dissolved in bacteriostatic water and administered subcutaneously or intramuscularly. Oral BPC-157 is taken as capsules or dissolved in water. Animal studies show both routes produce systemic effects, though bioavailability data for oral dosing in humans is essentially absent. Oral may be more practical for gut-related applications based on proximity of contact, but this is mechanistic reasoning, not proven human pharmacokinetics.
How do I read a COA for BPC-157?
A credible COA should show: HPLC purity above 98 percent, mass spectrometry confirmation of molecular weight 1419.55 Da, endotoxin testing below 1 EU/mg for injectable use, and sterility testing if sold as injectable-grade. COAs from the supplier's own in-house lab carry lower evidentiary weight than those from independent third-party labs.
What dose is used in animal studies and does it translate to humans?
Most rat studies by Sikiric et al. have used doses ranging from roughly 10 mcg/kg to 10 mg/kg depending on the model. Simple allometric scaling to humans is not validated for BPC-157. Community-reported human doses typically range from 200 to 500 mcg per day, but these are not derived from human pharmacokinetic trials. There are no published dose-finding studies in humans.
How should BPC-157 be stored after reconstitution?
Lyophilized BPC-157 powder should be stored at 2 to 8 degrees Celsius and protected from light and humidity. After reconstitution with bacteriostatic water, the solution should be refrigerated and used within approximately 4 weeks, as peptide bonds degrade in aqueous solution due to hydrolysis. Freeze-thaw cycles accelerate degradation and should be avoided.
Is BPC-157 detectable on drug tests?
BPC-157 is on the WADA prohibited list under peptide hormones and related substances. WADA-accredited labs can test for it. If you are subject to sports anti-doping rules, using BPC-157 is a violation regardless of how it was obtained.
What is the strongest evidence that BPC-157 works?
The strongest evidence is from animal models showing accelerated tendon, ligament, and gut tissue healing. Sikiric's group has published extensively on rodent models. There are no published randomized controlled trials in humans. Current evidence does not meet the standard required for clinical recommendation.
How does BPC-157 compare to other healing peptides like TB-500?
TB-500 and BPC-157 are both studied for musculoskeletal recovery. Both have animal-model evidence. TB-500 acts primarily through actin regulation and angiogenesis; BPC-157 appears to work through nitric oxide pathways and growth hormone receptor modulation. Neither has completed a human RCT for injury healing.
What are the main risks of self-administering BPC-157 from a research supplier?
Key risks include injection site infection from non-sterile preparation, unknown impurities from non-GMP manufacturing, incorrect dosing from impure product, and no physician oversight if adverse effects occur. No serious adverse events have been formally reported in peer-reviewed human studies, but this partly reflects the near-total absence of human trials, not proven safety.
Sources
- Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16):1612-1632. PubMed PMID: 21548867.
- Sikiric P, et al. Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design. 2013;19(1):76-83. PubMed PMID: 22950483.
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774-780. PubMed PMID: 21148344.
- Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. 2003;21(6):976-983. PubMed PMID: 14554209.
- FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Category 2 list. Available at: fda.gov. Accessed 2026.
- WADA. World Anti-Doping Agency Prohibited List 2024. Available at: wada-ama.org. Accessed 2026.
- Sikiric P, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Neuropharmacology. 2016;14(8):857-865. PMC5333585.
- Janoshik Analytical. Independent peptide purity testing reports. Available at: janoshik.com. Various dates accessed 2024 to 2026.
- United States Pharmacopeia (USP). General Chapter 1 Injections and Implanted Drug Products. USP-NF. Accessed 2026.